SCHEMBL654847

SCHEMBL654847

[C]1=C\C=C/c2ccccc2\N=N/1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18935567 0.71
SCHEMBL6843536 0.70 MAPT (0.39)
SCHEMBL4500210 0.67
SCHEMBL4500203 0.67
SCHEMBL18321041 0.65
SCHEMBL18321043 0.65
SCHEMBL8652346 0.65
SCHEMBL8652341 0.65
SCHEMBL10735757 0.64 TRPA1 (0.31)
SCHEMBL10735763 0.64 TRPA1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030216414-A1 Method for preventing tissue injury from hypoxia CELL THERAPEUTICS,INC. 2003-11-20 US claimed
US-6638938-B1 By tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic CELL THERAPEUTICS, INC. 2003-10-28 US claimed
EP-0739203-A4 METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF CELL THERAPEUTICS INC (US) 2000-12-20 EP claimed
US-5985926-A VIRICIDES OF AMINE COMPOUNDS AND HYDROCARBONS CELL THERAPEUTICS, INC. (US) 1999-11-16 US claimed
US-5856331-A LYSOPHOSPHATIDIC ACYLTRANSFERASE INHIBITOR CELL THERAPEUTICS, INC. (US) 1999-01-05 US claimed
EP-0739203-A1 METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF CELL THERAPEUTICS, INC. (US) 1996-10-30 EP claimed
EP-0728003-A1 METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA CELL THERAPEUTICS, INC. (US) 1996-08-28 EP claimed
EP-0676958-A1 METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION CELL THERAPEUTICS, INC. (US) 1995-10-18 EP claimed
WO-1995019171-A1 METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF CELL THERAPEUTICS, INC. (US) 1995-07-20 WO claimed
WO-1995013075-A1 METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA CELL THERAPEUTICS, INC. (US) 1995-05-18 WO claimed
WO-1995012396-A1 METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION CELL THERAPEUTICS, INC. (US) 1995-05-11 WO claimed
US-20240231224-A9 HALOGEN-AND ALIPHATIC-CONTAINING ORGANOTIN PHOTORESISTS AND METHODS THEREOF LAM RESEARCH CORPORATION 2024-07-11 US disclosed
WO-2024137876-A2 SURFACE MODIFICATION OF METAL CATALYSTS WITH HYDROPHOBIC LIGANDS OR IONOMERS TWELVE BENEFIT CORPORATION (US) 2024-06-27 WO disclosed
US-20240200208-A1 CO2 PURIFICATION AND REDUCTION SYSTEMS SUMITOMO MITSUI BANKING CORPORATION 2024-06-20 US disclosed
WO-2024123514-A1 CO2 PURIFICATION AND REDUCTION SYSTEMS TWELVE BENEFIT CORPORATION (US) 2024-06-13 WO disclosed
EP-0728003-A1 METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA CELL THERAPEUTICS, INC. (US) 1996-08-28 EP disclosed
EP-0676958-A1 METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION CELL THERAPEUTICS, INC. (US) 1995-10-18 EP disclosed
WO-1995019171-A1 METHOD FOR TREATING DISEASES MEDIATED BY CELLULAR PROLIFERATION IN RESPONSE TO PDGF, EGF, FGF AND VEGF CELL THERAPEUTICS, INC. (US) 1995-07-20 WO disclosed
WO-1995013075-A1 METHOD FOR PREVENTING TISSUE INJURY FROM HYPOXIA CELL THERAPEUTICS, INC. (US) 1995-05-18 WO disclosed
WO-1995012396-A1 METHOD FOR INHIBITING INTRACELLULAR VIRAL REPLICATION CELL THERAPEUTICS, INC. (US) 1995-05-11 WO disclosed